Conclusions reached by a Centers for Medicare & Medicaid Services advisory committee suggest that national coverage of beta amyloid PET imaging agents will have to wait at least two years for data demonstrating a benefit on health outcomes in patients with early symptoms of cognitive dysfunction.

CMS's Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) met Jan. 30 to discuss a National Coverage Assessment (NCA) for beta amyloid PET imaging for diagnosing and managing dementia and neurodegenerative disease.